Investors & Media

New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer’s disease

Phase 1b study showed dose-dependent and sustained reduction of tau protein in cerebrospinal fluid through open-label long-term extension (LTE) IONIS-MAPT Rx reduced aggregated tau pathology across all brain composites assessed starting as early as week 25 through week 100 CARLSBAD, Calif.

Read more
You are now leaving to visit